¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inlay bone graft"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 3
¿µ¹® mandibular bone, mandible ÇÑ±Û ¾Æ·¡ÅλÀ, ÇϾǰñ
¼³¸í   
  ¾ó±¼À» ±¸¼ºÇϴ »ÀÀÇ ÇÑ Á¾·ù·Î½á, ÈçÈ÷ ¸»Çϴ "ÅÎ"À» ÀÌ·ç´Â »À¸¦ ¸»ÇÑ´Ù. ¾ó±¼»À¸¦ ÀÌ·ç´Â »À´Â À§ÅλÀ(maxillary bone), ¾Æ·¡»À(mandibular bone), ´«¹°»À(lacrimal bone), ÄÚ»À(nasal bone), ±¤´ë»À(zygomatic bone), º¸½À»À(vomer) µîÀÌ ÀÖ´Ù.
  
  
  
  
¿µ¹® red bone marrow ÇÑ±Û Àû»ö°ñ¼ö
¼³¸í   
  ºÐÈ­ÁßÀÇ °¥ºñ»À, Ã´Ãß»À³ª ±× ¿ÜÀÇ ¸¹Àº ÀÛÀº »À¿¡ Àִ Ȱµ¿¼º °ñ¼öÀÌ´Ù. ÀûÇ÷±¸³ª °ú¸³¹éÇ÷±¸ÀÇ »ý»ê Àå¼ÒÀÌ´Ù.
¿µ¹® nasal bone ÇÑ±Û ÄÚ»À
¼³¸í   
  ÄڻѸ®ÀÇ ±âÃʸ¦ ÀÌ·ç´Â »ç´Ù¸®²ÃÀÇ ¾ãÀº »À·Î Á¿ì ÇÑ ½ÖÀÇ ¹°··»ÀÀ̸ç, Á¤Áß¾Ó¼±¿¡¼­ ºÙ¾î ÀÖ´Ù. ÄÚ»ÀÀÇ À­¸ð¼­¸®´Â À̸¶»À, ¾Æ·¡¸ð¼­¸®´Â ÄÚ¼±¹Ý¿¬°ñ, °¡Âʸ𼭸®´Â À§ÅλÀÀ̸¶µ¹±â¿Í Á¢ÇÑ´Ù. ¹Ù±ù¸éÀº ÆòȰÇÏÁö¸¸ ¼Ó¾È¸éÀº ¿ä¸éÀ» ÀÌ·ç¸ç, ¼¼·Î·Î °ÉÄ£ ¹úÁý»À½Å°æ±¸´Â ÄÚ»À±¸¸ÛÀ¸·Î ¿¬°áµÇ¾î ¾Õ¹úÁý»À½Å°æ°ú ÅëÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cultured keratinocyte graft
    ¹è¾ç°¢Áú¼¼Æ÷À̽Ä
  • cartilage graft
    ¿¬°ñÀÌ½ÄÆí
  • chorioallantoic graft
    À¶¸ð¿ä¸·À̽Ä
  • double-end graft
    ¾ç³¡À̽Ä, ½Ö´ÜÀ̽Ä
  • free graft
    À¯¸®ÀÌ½ÄÆí
  • free jejunal graft
    À¯¸®ºóâÀÚÀ̽Ä(¼ú), À¯¸®°øÀåÀ̽Ä(¼ú)
  • full-thickness graft
    ÀüÃþÇǺÎÀ̽Ä
  • gauntlet graft
    Àå°©¸ð¾çÀ̽İñÆí
  • graft
    1. ÀÌ½Ä 2. ÀÌ½ÄÆí
  • graft atherosclerosis
    ÀÌ½ÄÆíÁ×°æÈ­(Áõ), ÀÌ½ÄÆíÁ׸ð¾ç°æÈ­(Áõ)
  • graft recipient
    1. ÀÌ½ÄÆí¹Þ´ÂÀÌ 2. ÀÌ½ÄÆí¹Þ´ÂºÎÀ§
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ¹ÝÀÀ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • heterodermic graft
    ÀÌÁ¾ÇǺÎÀ̽Ä
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • bone deposition
    »ÀÄ§Âø, °ñÄ§Âø
  • bone marrow depression
    °ñ¼ö±â´É¾ïÁ¦
  • bone fragment
    »ÄÁ¶°¢
  • bone conduction hearing
    »ÀÀüµµµè±â, »ÀÀüµµÃ»·Â
  • bone knife
    »ÀÄ®, °ñµµ
  • bone marrow
    »Ä¼ÓÁú, °ñ¼ö
  • bone matrix
    »À¹ÙÅÁÁú
  • bone scan
    »À½ºÄµ
  • bone screw
    »À³ª»ç, °ñ³ª»ç
  • bone structure
    »À±¸Á¶, °ñ±¸Á¶
  • facial bone contouring surgery
    ¾ó±¼»ÀÀ±°û±³Á¤¼ú
  • bone marrow transplantation
    °ñ¼öÀ̽Ä(¼ú)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • coronary artery bypass graft
    ½ÉÀ嵿¸Æ¿ìȸ¼ú
  • costal cartilage graft
    °¥ºñ¿¬°ñÀ̽Ä, ´Á¿¬°ñÀ̽Ä
  • cultured keratinocyte graft
    ¹è¾ç°¢Áú¼¼Æ÷À̽Ä
  • double-end graft
    ¾ç³¡À̽Ä, ½Ö´ÜÀ̽Ä
  • graft-versus-host disease
    À̽Ĵë¼÷ÁÖº´
  • free graft
    À¯¸®À̽Ä
  • free jejunal graft
    À¯¸®ºóâÀÚÀ̽ļú, À¯¸®°øÀåÀ̽ļú
  • full-thickness graft
    ÀüÃþÇǺÎÀ̽Ä
  • graft
    À̽Ä, ÀÌ½ÄÆí
  • gauntlet graft
    Àå°©¸ð¾çÀ̽İñÆí
  • graft recipient
    ÀÌ½ÄÆí¹Þ´ÂÀÌ
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ
  • graft schizophrenia
    (¢¡propf schizophrenia) À̽ÄÁ¤½ÅºÐ¿­º´
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • heterodermic graft
    ÀÌÁ¾ÇǺÎÀ̽Ä
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • graft versus host disease
    ´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´.
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • graft, free jejunal
    À¯¸®°øÀå À̽ļú
  • graft, heterotopic
    À̼ÒÀ̽Ä, ´Ù¸¥ÀÚ¸®À̽Ä
  • graft, nerve
    ½Å°æÀ̽Ĺý
  • graft, orthotopic
    µ¿¼ÒÀ̽Ä, °°ÀºÀÚ¸®À̽Ä
  • graft, perichondral cutaneous
    ¿¬°ñ¸·ÇǺÎÀ̽Ä
  • graft, second
    ÀÌÂ÷À̽Ä
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë ¼÷ÁÖº´
  • heterodermic graft
    ÀÌÁ¾½ÄÇÇ(ì¶ðúãÕù«)
  • heteroplastic graft
    ÀÌÁ¾½ÄÇÇ(¡­ãÕù«)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • bypass graft
    ¿ìȸ·Î À̽Ä(Á¶¼º)¼ú(éæüÞÖØì¹ãÕ[ðãà÷]âú).
  • cartilage graft
    ¿¬°ñÀ̽Ä
  • chorioallantoic graft
    À¶¸ð¿ä¸·À̽Ä(ëÖÙ¾èñدì¹ãÕ).
  • collagen graft
    ±³¿øÁúÀ̽Ä
  • composite graft
    º¹ÇÕÁ¶Á÷À̽Ä.
  • corneal graft
    °¢¸·ÀÌ½ÄÆí(¡­ì¹ãÖ).
  • coronary artery bypass graft
    °ü»óµ¿¸Æ¿ìȸ·Î¼úÀ̽Ä(¼ú).
  • coronary artery bypass graft
    °ü»óµ¿¸Æ¿ìȸ·Î¼úÀ̽Ä(¼ú).
  • cultured keratinocyte graft
    ¹è¾ç°¢Áú¼¼Æ÷ À̽Ä
  • dermic graft
    ½ÄÇÇ(½ÄÇÇ).
  • dermis graft
    ÁøÇÇÀ̽Ä
  • double-end graft
    ½Ö´ÜÀ̽Ä.
  • dural graft
    °æ¸·À̽Ä(°æ¸·À̽Ä).
  • epidermic graft
    Ç¥ÇÇÀ̽Ä(¡­ì¹ãÕ).
  • fascia graft
    ±Ù¸· À̽Ä(ÐÉØ¯ì¹ãÕ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Greater horn of hyoid bone
    ¸ñ»Ô»ÀÅ«»Ô
    [¿¾ ¿ë¾î] ¼³°ñ´ë°¢
  • Immature compact bone
    ¹Ì¼º¼÷Ä¡¹Ð»À
    [¿¾ ¿ë¾î] ÀüÄ¡¹Ð°ñ
  • Lunate bone
    ¹Ý´Þ»À
    [¿¾ ¿ë¾î] ¿ù»ó°ñ
  • Articular surface for navicular bone
    ¹ß¹è°üÀý¸é
    [¿¾ ¿ë¾î] ÁÖ»ó°ñ°üÀý¸é
  • Navicular bone
    ¹ß¹è»À
    [¿¾ ¿ë¾î] ÁÖ»ó°ñ
  • Tuberosity of navicular bone
    ¹ß¹è»À°ÅÄ£¸é
    [¿¾ ¿ë¾î] ÁÖ»ó°ñÁ¶¸é
  • Head of metatarsal bone
    ¹ßÇ㸮»À¸Ó¸®
    [¿¾ ¿ë¾î] ÁßÁ·(ô)°ñµÎ
  • Body of metatarsal bone
    ¹ßÇ㸮»À¸öÅë
    [¿¾ ¿ë¾î] ÁßÁ·(ô)°ñü
  • Base of metatarsal bone
    ¹ßÇ㸮»À¹Ù´Ú
    [¿¾ ¿ë¾î] ÁßÁ·(ô)°ñÀú
  • Irregular bone
    ºÒ±ÔÄ¢»À
    [¿¾ ¿ë¾î] ºÒ±ÔÄ¢°ñ
  • Canaliculus of bone
    »À¸ð¼¼°ü
    [¿¾ ¿ë¾î] °ñ¼Ò°ü
  • Bone matrix
    »À¹ÙÅÁÁú
    [¿¾ ¿ë¾î] °ñ±âÁú
  • Lacuna of bone
    »À¹æ
    [¿¾ ¿ë¾î] °ñ¼Ò°­
  • Trabecula of bone
    »ÀÀܱâµÕ
    [¿¾ ¿ë¾î] °ñ¼ÒÁÖ
  • Lamella of bone
    »ÀÃþÆÇ
    [¿¾ ¿ë¾î] °ñÃþÆÇ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hammer bone
    ¸ÁÄ¡»À, Ãß°ñ
  • herring bone appearance
    û¾î»À¸ð¾ç
  • hip bone
    °ü°ñ
  • iliac bone
    Àå°ñ
  • long bone
    Àå°ñ
  • malar bone
    Çù°ñ
  • marble bone
    ´ë¸®¼®°ñ
  • marble bone disease
    ´ë¸®¼®°ñº´
  • maxillary bone
    »ó¾Ç°ñ
  • membranous bone
    ¸·°ñ
  • metacarpal bone
    Áß¼ö°ñ
  • metatarsal bone
    ÁßÁ·°ñ
  • navicular bone
    ¹ß¹è°ñ, ÁÖ»ó°ñ
  • new bone formation
    ½Å°ñÇü¼º
  • occipital bone
    逵롖
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ACBG aortocoronary bypass graft
ACG accelerator globulin; alternative care grant; ambulatory care group; American College of Gastroenter...
ACSVBG aortocoronary saphenous vein bypass graft
AFBG aortofemoral bypass graft
BPG benzathine penicillin G; D-2,3-bisphosphoglycerate; blood pressure gauge; bypass graft
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
GVD Graft vascular disease
GvH Graft versus Host
GVH Graft versus host reaction
GVHR Graft versus host reaction
GVL Graft versus leukemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • full thickness graft
    ÀüÃþ ÇǺΠÀÌ½ÄÆí, ÀüÃþ ½ÄÇÇ
  • heterodermic graft
    ÀÌÁ¾ ÇǺΠÀÌ½ÄÆí
    ÀÌÁ¾ µ¿¹°¿¡¼­ ¾òÀº ÇǺΠÀÌ½ÄÆí.
  • heterologous graft
    ÀÌÁ¾ À̽Ä
    ÀÌÁ¾ÀÇ µ¿¹°°£¿¡ À̽ĵǴ Á¶Á÷Æí.
  • hyperplastic graft
    Áõ½Ä¼º À̽Ä
    ¿°ÁõÀ¸·ÎºÎÅÍ È¸º¹ÇÏ´Â »óÅÂ¿Í °°Àº Ȱµ¿Àû º¹¿ø »óÅ¿¡¼­ÀÇ ÇǺΠÀ̽Ä.
  • lamellar graft
    ÃþÆÇ À̽Ä
    ºÒÅõ¸íÇÑ °¢¸·ÀÇ Ç¥ÃþÀ» Á¦°ø ¾ÈÀÇ Åõ¸íÇÑ °¢¸·ÀÇ ¹ÚÃþ°ú ¹Ù²Ù´Â À̽Ä.
  • muscle graft
    ±ÙÀ° À̽Ä
  • Ollier-Thiersch graft
    ¿Ã¸®¿¡¸£ Ƽ¸£½¬ ÀÌ½ÄÆí
    »óÇÇÃþ, »óÇǸÁ, ÁøÇÇÀÇ ÀϺθ¦ Æ÷ÇÔÇÑ ¸Å¿ì ¾ã°í ³ÐÀº ÇǺΠÀÌ½ÄÆí.
  • omental graft
    ´ë¸Á À̽Ä
    ºÀÇÕ¼±À» µ¤±â À§ÇÏ¿© »ç¿ëµÇ´Â À¯¸®µÇ°Å³ª Àý´ÜµÇÁö ¾ÊÀº ´ë¸ÁÀÇ ºÐÀý. À§Àå ¹× °áÀå ¼ö¼ú ÈÄ¿¡ »ç¿ëµÈ´Ù.
  • osseous graft
    °ñ À̽Ä, °ñ ÀÌ½ÄÆí
  • osteoperiosteal graft
    °ñ¸· À̽Ä
  • patch graft
    øºÎ ÀÌ½ÄÆí
    Ç÷°ü°­À» È®´ëÇϱâ À§ÇÏ¿© Ç÷°ü Àý°³ºÎ¸¦ ¸·´Â µ¥ »ç¿ëµÇ´Â À̽Ŀë Á¶Á÷ ¶Ç´Â ÀÎÁ¶ ¹°Áú.
  • pedicle graft
    °æ»ó ÀÌ½ÄÆí
  • penetrating graft
    °üÅë À̽Ä
    °¢¸·ÀÇ ÀüÃþ À̽Ä.
  • perichondral bony ring

    perichondral cutaneous graft

    ¿¬°ñ¸· ÇǺΠÀ̽Ä
  • periosteal graft
    °ñ¸· À̽Ä, °ñ¸· ÀÌ½ÄÆí
    °ñÀÇ ¹þ°ÜÁø ºÎÀ§¿¡ »ç¿ëµÇ´Â °ñ¸·Æí.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
graft rejection <haematology, immunology> When donated bone marrow infused during a bone marrow transplant is rejected by the patients body or does not take.
(16 Dec 1997)
graft survival <haematology> The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
(12 Dec 1998)
graft-versus-host disease <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host reaction <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
mesh graft A skin graft in which multiple slits have been made, so it can be stretched to cover a large area.
Synonym: mesh graft.
(05 Mar 2000)
periosteal graft A graft of periosteum, usually placed on bare bone.
(05 Mar 2000)
chip graft A graft utilizing small pieces of cartilage or bone which is packed into a bone defect.
(05 Mar 2000)
chorioallantoic graft Transplanting of living material to the chorioallantoic membrane of the embryonic chick.
(05 Mar 2000)
Phemister graft An autogenous onlay bone graft used in treating delayed union of fractures.
(05 Mar 2000)
pinch graft Small bits of skin, of partial or full thickness, removed from a healthy area and seeded in a site to be covered.
Synonym: Reverdin graft.
(05 Mar 2000)
white graft Rejection of a skin allograft so acute that vascularization never occurs.
(05 Mar 2000)
composite graft A graft composed of several structures, such as skin and cartilage or a full-thickness segment of the ear.
(05 Mar 2000)
mucosal graft A graft of mucous membrane, usually the full-thickness of the lining of the cheek or lower lip.
(05 Mar 2000)
Wolfe graft A full-thickness skin graft without any subcutaneous fat.
Synonym: Wolfe-Krause graft.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á